In the last trading session, 4.76 million Regulus Therapeutics Inc (NASDAQ:RGLS) shares changed hands as the company’s beta touched 0.92. With the company’s per share price at $3.49 changed hands at $0.73 or 26.45% during last session, the market valuation stood at $231.19M. RGLS’s last price was a premium, traded about 16.91% off its 52-week high of $2.90. The share price had its 52-week low at $0.83, which suggests the last value was 76.22% up since then. When we look at Regulus Therapeutics Inc’s average trading volume, we note the 10-day average is 1.34 million shares, with the 3-month average coming to 1.24 million.
Analysts gave the Regulus Therapeutics Inc (RGLS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RGLS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Regulus Therapeutics Inc’s EPS for the current quarter is expected to be -0.26.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
Instantly RGLS was in green as seen at the end of in last trading. With action 73.63%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 120.89%, with the 5-day performance at 73.63% in the green. However, in the 30-day time frame, Regulus Therapeutics Inc (NASDAQ:RGLS) is 132.67% up. Looking at the short shares, we see there were 2.11 million shares sold at short interest cover period of 0.94 days.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 40.21%. The 2025 estimates are for Regulus Therapeutics Inc earnings to decrease by -42.89%, but the outlook for the next 5-year period is at -3.70% per year.
RGLS Dividends
Regulus Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.18% of Regulus Therapeutics Inc shares while 86.69% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 88.63%. There are 86.69% institutions holding the Regulus Therapeutics Inc stock share, with FEDERATED HERMES, INC. the top institutional holder. As of 2024-06-30, the company held 19.9374% of the shares, roughly 12.85 million RGLS shares worth $22.94 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 9.6952% or 6.25 million shares worth $11.16 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund . With 7.88 shares estimated at $27.5 million under it, the former controlled 11.90% of total outstanding shares. On the other hand, Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund held about 11.20% of the shares, roughly 7.42 shares worth around $25.89 million.
